Background and Purpose—Limited evidence exists on the effectiveness and safety of
warfarin and all 4 available non-vitamin K antagonist oral anticoagulants (NOACs) from …

Background and Purpose—Limited data are available describing the relative effectiveness,
safety, and optimal dosing of non–vitamin K antagonist oral anticoagulants (NOACs) for …

Background and Purpose—There are limited real-world data comparing the effectiveness
and safety of non-vitamin K antagonist oral anticoagulants (NOACs) and warfarin in Asians …

Background Although randomized trials provide a high level of evidence regarding the
efficacy of non-vitamin K oral anticoagulants (NOACs), the results of such trials may differ …

Background and Purpose—This ARISTOPHANES study (Anticoagulants for Reduction in
Stroke: Observational Pooled Analysis on Health Outcomes and Experience of Patients) …

Objective To assess the safety (ie, risk of bleeding) and effectiveness (ie, risk of
stroke/systemic embolism (SE)) separately for four non-vitamin K oral anticoagulants …

Background Much direct evidence has proved that the novel oral anticoagulants (NOACs)
are noninferior or superior to warfarin for stroke prevention in patients with nonvalvular atrial …

Background Whether four direct oral anticoagulants (DOACs) are superior to warfarin in
Asian patients with nonvalvular atrial fibrillation (NVAF) remains unclear. Methods This …

Background and Purpose—The use of vitamin K antagonists (VKAs), the cornerstone
treatment for stroke prevention in patients with atrial fibrillation, is limited by the perceived …

The incidence of intracranial bleeding is known to be markedly higher in Japan and other
East Asian countries than in countries outside of East Asia. Non-vitamin K antagonist oral …